Bleomycin/cis-platin as neoadjuvant chemotherapy before radical radiotherapy in localized, inoperable carcinoma of the esophagus. A prospective randomized multicentre study: the second Scandinavian trial in esophageal cancer.
Survival and swallowing function were studied in a randomized trial of 97 patients with inoperable, localized esophageal carcinoma. Radical radiotherapy was given to 51 patients, while 46 patients had two courses of bleomycin/cisplatin before radiotherapy. The survival was 29% after one year, and 6% after 3 years in the radiotherapy group. The survival in the combined treatment group was 18 and 0%, respectively; p = 0.1895. The number of patients who could swallow any food increased from 6% before treatment to 38% after 3 months in the radiotherapy group, and from 0% to 23% in the combined group. No benefit was found by combining bleomycin/cisplatin with radiotherapy.
Hatlevoll
R
R
Norwegian Radium Hospital, Oslo.
Hagen
S
S
Hansen
H S
HS
Hultborn
R
R
Jakobsen
A
A
Mäntylä
M
M
Modig
H
H
Munck-Wikland
E
E
Nygaard
K
K
Rosengren
B
B
D000368:Aged; D001761:Bleomycin / Q000008:administration & dosage / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003679:Deglutition / Q000187:drug effects / Q000502:physiology / Q000528:radiation effects; D004938:Esophageal Neoplasms / Q000188:drug therapy / Q000453:epidemiology / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012537:Scandinavian and Nordic Countries / Q000453:epidemiology; D015996:Survival Rate
D001761:Bleomycin; D002945:Cisplatin